- Gene Therapy Improves Vision in People With Inherited Blindness
- Parental Deaths to Guns, Drugs Harmed Nearly 100,000 U.S. Kids in 2020
- Money Worries Top Seniors’ List of Health-Related Concerns: Poll
- Scientists Developing Vaccine Against Present and Future COVID Viruses
- ERs Often Missing Epilepsy in Kids With ‘Non-Motor’ Seizures
- Parents of Infants With Cystic Fibrosis Often Feel Confused, Unsupported: Survey
- Avoid Some ‘Project Watson’ Dog Eye Wipes Due to Infection Danger
- New Test Might Alert Pregnant Women to Preeclampsia Danger
- Combo Therapy May Be Advance Against Liver Cancer
- How ‘Unruly’ Sports Parents Harm Their Kids’ Mental Health
Xtoro Approved for Swimmer’s Ear
Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer’s ear, clinically known as acute otitis externa.
The infection of the outer ear and ear canal, most often caused by ear canal bacteria, has typical symptoms including pain, swelling, redness and discharge, the FDA said in a news release.
The drug’s safety and effectiveness were evaluated in a clinical study of more than 1,200 people, aged 6 months to 85 years. The most common side effects were ear itching and nausea.
Xtoro is produced by Alcon Laboratories, based in Fort Worth, Texas.
More information
The FDA has more about this approval.
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.